# Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer

> **NCT00019656** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Leukemia
- Lymphoma
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** perifosine

## Key facts

- **NCT ID:** NCT00019656
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2015-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00019656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00019656, "Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00019656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*